In 2006, Robert E. Johnston, Ph.D. and Clayton W. Beard, Ph.D., opened the doors of Global Vaccines, Inc (GVI), a not-for-profit company, spinning out from the University of North Carolina at Chapel Hill, in order to develop new vaccines free from the limitations of high profit-margin requirements. The company develops platform vaccine technologies that can be applied to a broad spectrum of disease targets selected on the basis of global public health needs rather than market potential. It is located in the Research Triangle Park in North Carolina.
- Carroll TD, Matzinger SR, Barro M, Fritts L, McChesney MB, Miller CJ, Johnston RE (2011). "Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone® in rhesus macaques". Vaccine. 29 (5): 931–940. doi:10.1016/j.vaccine.2010.11.024. PMC 3026063. PMID 21111777.
- LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS (2009). "Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge". J. Virol. 83 (7): 3212–3227. doi:10.1128/JVI.01650-08. PMC 2655567. PMID 19176631.